Literature DB >> 29393211

The Radboud Dysarthria Assessment: Development and Clinimetric Evaluation.

Simone Knuijt1, Johanna G Kalf1, Baziel G M van Engelen2, Bert J M de Swart1,3, Alexander C H Geurts1.   

Abstract

OBJECTIVE: In the absence of an adequate dysarthria assessment in the Netherlands, we developed the Radboud Dysarthria Assessment (RDA). This article describes its development and clinimetric evaluation. PATIENTS AND METHODS: Forty-three patients were assessed with the RDA. The recording forms were subjected to exploratory factor analysis and estimation of internal consistency. The self-evaluation questionnaire was tested for internal consistency and the severity scale for intra- and inter-rater reliability. Construct validity of the severity scale and questionnaire was determined by relating them to the Speech Handicap Index (SHI), Dutch sentence intelligibility assessment (NSVO-Z), and category fluency task.
RESULTS: Exploratory factor analysis extracted 4 factors (articulation, resonance, phonation, respiration/prosody) yielding an explained variance of 70.3%. Each factor showed good internal consistency (Cronbach's α: 0.89-0.91). The self-evaluation questionnaire showed excellent internal consistency (Cronbach's α: 0.90). Intra-class correlation coefficients of the severity scale (0.85-0.86) showed good reliability. The severity scores and self-evaluation questionnaire correlated substantially to strongly with the SHI (rs = 0.40 and 0.80) and substantially with the NSVO-Z (rs = -0.65 and -0.52).
CONCLUSIONS: The RDA is a valid and reliable tool, but further investigation is needed to demonstrate whether this instrument can successfully support speech-language therapists in correctly diagnosing the type of dysarthria.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Assessment; Dysarthria; Validation

Mesh:

Year:  2018        PMID: 29393211     DOI: 10.1159/000484556

Source DB:  PubMed          Journal:  Folia Phoniatr Logop        ISSN: 1021-7762            Impact factor:   0.849


  7 in total

1.  Validation of the pediatric Radboud Dysarthria Assessment.

Authors:  Marieke Ruessink; Lenie van den Engel-Hoek; Marjo van Gerven; Bea Spek; Bert de Swart; Johanna Kalf
Journal:  J Pediatr Rehabil Med       Date:  2022

2.  Everyday Activities for Children with Mitochondrial Disorder: A Retrospective Chart Review.

Authors:  Marieke Lindenschot; Imelda J M de Groot; Saskia Koene; Ton Satink; Esther M J Steultjens; Maria W G Nijhuis-van der Sanden
Journal:  Occup Ther Int       Date:  2018-06-06       Impact factor: 1.448

3.  Design of the PERSPECTIVE study: PERsonalized SPEeCh Therapy for actIVE conversation in Parkinson's disease (randomized controlled trial).

Authors:  J J L Maas; N M De Vries; B R Bloem; J G Kalf
Journal:  Trials       Date:  2022-04-08       Impact factor: 2.279

4.  Impact of oral motor task training on corticomotor pathways and diadochokinetic rates in young healthy participants.

Authors:  Noéli Boscato; Hidetoshi Hayakawa; Takashi Iida; Yuri M Costa; Simple Futarmal Kothari; Mohit Kothari; Peter Svensson
Journal:  J Oral Rehabil       Date:  2022-06-30       Impact factor: 3.558

5.  Dysphagia and Dysarthria in Children with Neuromuscular Diseases, a Prevalence Study.

Authors:  Mieke Kooi-van Es; Corrie E Erasmus; Bert J M de Swart; Nicoline B M Voet; Philip J van der Wees; Imelda J M de Groot; Lenie van den Engel-Hoek
Journal:  J Neuromuscul Dis       Date:  2020

6.  Swallowing, Chewing and Speaking: Frequently Impaired in Oculopharyngeal Muscular Dystrophy.

Authors:  Rosemarie H M J M Kroon; Corinne G C Horlings; Bert J M de Swart; Baziel G M van Engelen; Johanna G Kalf
Journal:  J Neuromuscul Dis       Date:  2020

7.  Longitudinal Assessment of Strength, Functional Capacity, Oropharyngeal Function, and Quality of Life in Oculopharyngeal Muscular Dystrophy.

Authors:  Rosemarie H M J M Kroon; Johanna G Kalf; Bert J M de Swart; Barbara M van der Sluijs; Jeffrey C Glennon; Vered Raz; Baziel G van Engelen; Corinne G C Horlings
Journal:  Neurology       Date:  2021-08-11       Impact factor: 9.910

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.